His primary areas of study are Intensive care medicine, Pharmacology, Internal medicine, Microbiology and Micafungin. His work carried out in the field of Intensive care medicine brings together such families of science as Clinical microbiology, Evidence-based medicine, Therapeutic drug monitoring and Drug resistance. His Pharmacology research integrates issues from Antifungal, Antifungal drug and Toxicity.
His Internal medicine study combines topics in areas such as Gastroenterology, Aspergillosis and Posaconazole. His research in Micafungin intersects with topics in Pharmacokinetics, Caspofungin, Echinocandins and Echinocandin. His Surgery study incorporates themes from Invasive fungal disease, Allergy and Fungal pneumonia.
William W. Hope spends much of his time researching Pharmacokinetics, Pharmacology, Pharmacodynamics, Internal medicine and Intensive care medicine. William W. Hope has researched Pharmacokinetics in several fields, including Dose, Drug, Liter and Dosing. His study on Pharmacology also encompasses disciplines like
The study incorporates disciplines such as Cryptococcus neoformans, Antibiotics, Drug resistance, Microbiology and Galactomannan in addition to Pharmacodynamics. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Amphotericin B deoxycholate, Fluconazole and Surgery. His Intensive care medicine research incorporates elements of Antifungal, Antifungal drug, Aspergillosis and Transplantation.
William W. Hope mainly focuses on Pharmacokinetics, Internal medicine, Pharmacodynamics, Gastroenterology and Fluconazole. His Pharmacokinetics research is multidisciplinary, relying on both Liter, Dose, Dosing, Piperacillin and Drug. As a part of the same scientific family, William W. Hope mostly works in the field of Internal medicine, focusing on Amphotericin B deoxycholate and, on occasion, Interquartile range and Multicenter study.
His Pharmacodynamics study is related to the wider topic of Pharmacology. His Pharmacology study also includes fields such as
His main research concerns Pharmacokinetics, Pharmacodynamics, Internal medicine, Antibiotic resistance and Fluconazole. Pharmacology covers William W. Hope research in Pharmacokinetics. His biological study spans a wide range of topics, including In vivo and Dosing.
William W. Hope interconnects Gastroenterology, Amphotericin B deoxycholate and Voriconazole in the investigation of issues within Internal medicine. His research on Antibiotic resistance also deals with topics like
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Ben De Pauw;Thomas J. Walsh;J. Peter Donnelly;David A. Stevens.
Clinical Infectious Diseases (2008)
ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.
O.A. Cornely;M. Bassetti;T. Calandra;J. Garbino.
Clinical Microbiology and Infection (2012)
Laboratory diagnosis of invasive aspergillosis
WW Hope;TJ Walsh;DW Denning.
Lancet Infectious Diseases (2005)
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
Johan A. Maertens;Issam I. Raad;Kieren A. Marr;Thomas F. Patterson.
The Lancet (2016)
ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
O.A. Cornely;S. Arikan-Akdagli;E. Dannaoui;A.H. Groll.
Clinical Microbiology and Infection (2014)
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
Jason A Roberts;Jason A Roberts;Mohd H Abdul-Aziz;Jeffrey Lipman;Jeffrey Lipman;Johan W Mouton.
Lancet Infectious Diseases (2014)
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology
H. Ruth Ashbee;Rosemary Ann Barnes;Elizabeth M. Johnson;Malcolm D. Richardson.
Journal of Antimicrobial Chemotherapy (2014)
EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)*
Maiken C. Arendrup;Manuel Cuenca-Estrella;Cornelia Lass-Flörl;William Hope.
Clinical Microbiology and Infection (2012)
Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation
Andreas H. Groll;Elio Castagnola;Simone Cesaro;Jean Hugues Dalle.
Lancet Oncology (2014)
ESCMID guideline for the diagnosis and management of Candida diseases 2012:diagnostic procedures
M. Cuenca-Estrella;P. E Verweij;M. C Arendrup;S. Arikan-Akdagli.
Clinical Microbiology and Infection (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Weill Cornell Medicine
Statens Serum Institut
Instituto de Salud Carlos III
Royal Brisbane and Women's Hospital
Duke University
University of Manchester
Boston Children's Hospital
University of Manchester
University of Cologne
Aristotle University of Thessaloniki
Auburn University
Purdue University West Lafayette
Korea University
Syracuse University
International Crops Research Institute for the Semi-Arid Tropics
Utrecht University
Columbia University
University of La Rioja
Brown University
University of Melbourne
Leiden University
University of South Florida
University of Virginia
University of California, Los Angeles
The Royal Free Hospital
Kyoto University